ENTITY

Sinopep-Allsino Bio Pharmaceutical (688076 CH)

10
Analysis
Health CareChina
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. researches, develops, manufactures, and sells peptide drugs and small molecule drugs. The Company produces liraglutide, somalutide, alogliptin benzoate, bivalirudin, eptifibatide, and more. Sinopep-Allsino Bio Pharmaceutical applies its products in treatment of diabetes, cardiovascular diseases, tumors, and other fields.
more
15 Oct 2024 15:42

Quiddity Leaderboard CSI Medical Service Dec 24: US$271mn One-Way; 1x-4x ADV to Trade for Most Names

We estimate the CSI Medical December 2024 index rebalance to trigger flows of US$271mn one-way. Most of the expected ADDs/DELs have 1x-4x ADV to...

Share
23 Sep 2024 05:08

Quiddity Leaderboard CSI Medical Dec 24: 5 Changes Possible; Exp ADDs yet to Outperform Exp DELs

We expect US$187mn one-way flows. Most of the expected ADDs/DELs have 1x-4x ADV to trade. The expected ADDs have failed to outperform the the...

Share
05 Nov 2024 13:29

Quiddity Leaderboard STAR 50/100 Dec 24: Four Changes Possible for STAR 100

For the STAR 100 rebalance, we estimate one-way flow to be around US$130mn. The expected ADDs/DELs have around 0.6x-2.3x ADV to trade. We expect...

Share
04 Nov 2024 13:40

Quiddity Leaderboard CSI Medical Dec 24: Final Rankings; Exp ADDs Underperforming Exp DELs

We expect the index changes to be announced after market close on 29th November 2024. We currently estimate one-way flow to be US$248mn. Most...

Share
04 Nov 2024 06:20

STAR50/STAR100 Index Rebalance Preview: No Changes for STAR50; 5 for STAR100; US$2bn Trade

We forecast no changes for the STAR50 and 5 changes for the STAR100. Capping will result in passives selling SMIC. The forecast adds to the STAR100...

Logo
317 Views
Share
x